Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
25 nov. 2024 16h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
07 nov. 2024 16h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
07 nov. 2024 08h10 HE
|
Third Harmonic Bio
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
10 sept. 2024 16h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
26 août 2024 16h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 08h05 HE
|
Third Harmonic Bio
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $255.3...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
28 mai 2024 16h05 HE
|
Third Harmonic Bio
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
15 mai 2024 08h05 HE
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
28 mars 2024 08h30 HE
|
Third Harmonic Bio
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
26 mars 2024 08h05 HE
|
Third Harmonic Bio
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO,...